FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310554287> ?p ?o ?g. }

• W4310554287 endingPage "102492" @default.
• W4310554287 startingPage "102492" @default.
• W4310554287 abstract "Standard of care for patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is surgery followed by chemoradiotherapy (CRT) or definitive CRT. However, approximately 50 % of patients with LA SCCHN develop disease recurrence or metastasis within 2 years of completing treatment, and the outcome for these patients is poor. Despite this, the current treatment landscape for LA SCCHN has remained relatively unchanged for more than 2 decades, and novel treatment options are urgently required. One of the key causes of disease recurrence is treatment resistance, which commonly occurs due to cancer cells' ability to evade apoptosis. Evasion of apoptosis has been in part attributed to the overexpression of inhibitor of apoptosis proteins (IAPs). IAPs, including X-linked IAP (XIAP) and cellular IAP 1 and 2 (cIAP1/2), are a class of proteins that regulate apoptosis induced by intrinsic and extrinsic apoptotic pathways. IAPs have been shown to be overexpressed in SCCHN, are associated with poor clinical outcomes, and are, therefore, a rational therapeutic target. To date, several IAP inhibitors have been investigated; however, only xevinapant, a potent, oral, small-molecule IAP inhibitor, has shown clinical proof of concept when combined with CRT. Specifically, xevinapant demonstrated superior efficacy in combination with CRT vs placebo + CRT in a randomized, double-blind, phase 2 trial in patients with unresected LA SCCHN. Here, we describe the current treatment landscape in LA SCCHN and provide the rationale for targeting IAPs and the clinical data reported for xevinapant." @default.
• W4310554287 created "2022-12-12" @default.
• W4310554287 creator A5011675274 @default.
• W4310554287 creator A5024024612 @default.
• W4310554287 creator A5029309849 @default.
• W4310554287 creator A5038777347 @default.
• W4310554287 creator A5047207695 @default.
• W4310554287 creator A5079313296 @default.
• W4310554287 creator A5081937285 @default.
• W4310554287 creator A5086074491 @default.
• W4310554287 date "2023-02-01" @default.
• W4310554287 modified "2023-10-02" @default.
• W4310554287 title "Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck" @default.
• W4310554287 cites W1203651314 @default.
• W4310554287 cites W1540485610 @default.
• W4310554287 cites W1725759174 @default.
• W4310554287 cites W1971240021 @default.
• W4310554287 cites W1976457595 @default.
• W4310554287 cites W1984909958 @default.
• W4310554287 cites W1986241711 @default.
• W4310554287 cites W1998812648 @default.
• W4310554287 cites W1999622014 @default.
• W4310554287 cites W2001103299 @default.
• W4310554287 cites W2014357769 @default.
• W4310554287 cites W2021190575 @default.
• W4310554287 cites W2025522492 @default.
• W4310554287 cites W2033812051 @default.
• W4310554287 cites W2034269086 @default.
• W4310554287 cites W2041384893 @default.
• W4310554287 cites W2042409437 @default.
• W4310554287 cites W2044221648 @default.
• W4310554287 cites W2064299413 @default.
• W4310554287 cites W2069800916 @default.
• W4310554287 cites W2076506346 @default.
• W4310554287 cites W2091269867 @default.
• W4310554287 cites W2099624217 @default.
• W4310554287 cites W2102472118 @default.
• W4310554287 cites W2117692326 @default.
• W4310554287 cites W2125715557 @default.
• W4310554287 cites W2131487381 @default.
• W4310554287 cites W2139059024 @default.
• W4310554287 cites W2146245664 @default.
• W4310554287 cites W2148818765 @default.
• W4310554287 cites W2165737898 @default.
• W4310554287 cites W2517270641 @default.
• W4310554287 cites W2605995955 @default.
• W4310554287 cites W2770751728 @default.
• W4310554287 cites W2791318827 @default.
• W4310554287 cites W2801674830 @default.
• W4310554287 cites W2802542587 @default.
• W4310554287 cites W2805076370 @default.
• W4310554287 cites W2810610846 @default.
• W4310554287 cites W2898353693 @default.
• W4310554287 cites W2904675051 @default.
• W4310554287 cites W2947592840 @default.
• W4310554287 cites W2950370589 @default.
• W4310554287 cites W3000605006 @default.
• W4310554287 cites W3000936329 @default.
• W4310554287 cites W3010012359 @default.
• W4310554287 cites W3047211484 @default.
• W4310554287 cites W3081407493 @default.
• W4310554287 cites W3087617819 @default.
• W4310554287 cites W3087917480 @default.
• W4310554287 cites W3090880996 @default.
• W4310554287 cites W3128646645 @default.
• W4310554287 cites W3131983302 @default.
• W4310554287 cites W3138668495 @default.
• W4310554287 cites W3147500389 @default.
• W4310554287 cites W3162583084 @default.
• W4310554287 cites W3165789567 @default.
• W4310554287 cites W3198064628 @default.
• W4310554287 cites W3200779885 @default.
• W4310554287 cites W3201848090 @default.
• W4310554287 cites W4212903909 @default.
• W4310554287 cites W4213176353 @default.
• W4310554287 cites W4295837518 @default.
• W4310554287 doi "https://doi.org/10.1016/j.ctrv.2022.102492" @default.
• W4310554287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36640618" @default.
• W4310554287 hasPublicationYear "2023" @default.
• W4310554287 type Work @default.
• W4310554287 citedByCount "3" @default.
• W4310554287 countsByYear W43105542872023 @default.
• W4310554287 crossrefType "journal-article" @default.
• W4310554287 hasAuthorship W4310554287A5011675274 @default.
• W4310554287 hasAuthorship W4310554287A5024024612 @default.
• W4310554287 hasAuthorship W4310554287A5029309849 @default.
• W4310554287 hasAuthorship W4310554287A5038777347 @default.
• W4310554287 hasAuthorship W4310554287A5047207695 @default.
• W4310554287 hasAuthorship W4310554287A5079313296 @default.
• W4310554287 hasAuthorship W4310554287A5081937285 @default.
• W4310554287 hasAuthorship W4310554287A5086074491 @default.
• W4310554287 hasBestOaLocation W43105542871 @default.
• W4310554287 hasConcept C121608353 @default.
• W4310554287 hasConcept C126322002 @default.
• W4310554287 hasConcept C143998085 @default.
• W4310554287 hasConcept C185592680 @default.
• W4310554287 hasConcept C190283241 @default.
• W4310554287 hasConcept C2775975398 @default.

• next